<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> AP880414-0254 </DOCNO><FILEID>AP-NR-04-14-88 1424EDT</FILEID><FIRST>r f AM-Cyanamid-LeukemiaDrug     04-14 0176</FIRST><SECOND>AM-Cyanamid-Leukemia Drug,0183</SECOND><HEAD>New Leukemia Drug Available</HEAD><DATELINE>NEW YORK (AP) </DATELINE><TEXT>   A pharmaceutical company said Thursday it hasbegun selling a new leukemia drug, the fourth new cancer agentsince 1983 and the third leukemia drug in 10 years to gain federalapproval.   Novantrone mitoxantrone hydrochloride is to be used incombination with other agents for treating adults with acutenonlymphocytic leukemia, Lederle Laboratories said in a statement.   The disease strikes about 8,000 Americans a year, the statementsaid. The drug apparently disrupts the functioning of geneticmaterial in cancer cells, the company said.   Novantrone was approved by the Food and Drug Administration in1987, but the agency's official rating of the drug indicates itrepresents little or no advantage over other treatments.   The other three new cancer drugs approved in the past five yearsare etoposide for testicular cancer, approved in 1983; leuprolideacetate for advanced prostate cancer, 1985; and interferon,approved in 1986 to fight hairy cell leukemia, said Dr. JohnJohnson of the FDA.   Lederle is a division of American Cyanamid Co.</TEXT></DOC>